Antibody-drug Conjugate Information
General Information of This Antibody-drug Conjugate (ADC)
| ADC ID |
DRG0ISSIL
|
|||||
|---|---|---|---|---|---|---|
| ADC Name |
hCD46-19
|
|||||
| Synonyms |
hCD46 19
Click to Show/Hide
|
|||||
| Drug Status |
Investigative
|
|||||
| Indication |
In total 1 Indication(s)
Uterine sarcoma [ICD11:2C72]
Investigative
|
|||||
| Antibody Name |
Anti-CD46 mAb
|
Antibody Info | ||||
| Antigen Name |
Membrane cofactor protein (CD46)
|
Antigen Info | ||||
| Payload Name |
PNU-159682
|
Payload Info | ||||
| Therapeutic Target |
DNA topoisomerase 2-alpha (TOP2A)
|
Target Info | ||||
| Linker Name |
Hydrophilic cleavable linker 19
|
Linker Info | ||||
General Information of The Activity Data Related to This ADC
Discovered Using Patient-derived Xenograft Model
Revealed Based on the Cell Line Data
Full List of Activity Data of This Antibody-drug Conjugate
Discovered Using Patient-derived Xenograft Model
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) | ≈ 52.34% (Day 30) | Positive CD46 expression (CD46 +++/++) | ||
| Method Description |
In vivo efficacy of PNU-conjugated ADCs in NSCLC LU253 PDX subcutaneous models in NOD/SCID mice. A single dose of 0.5 mg/kg hCD46-19 ADC.
|
||||
| In Vivo Model | Non-small cell lung cancer PDX model (PDX: LU253 PDX) | ||||
| Experiment 2 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) | ≈ 77.34% (Day 30) | Positive CD46 expression (CD46 +++/++) | ||
| Method Description |
In vivo efficacy of PNU-conjugated ADCs in colorectal CR188 PDX subcutaneous models in NOD/SCID mice. A single dose of 0.5 mg/kg hCD46-19 ADC.
|
||||
| In Vivo Model | Colorectal cancer PDX model (PDX: CR188 PDX) | ||||
| Experiment 3 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) | ≈ 86.67% (Day 30) | Positive CD46 expression (CD46 +++/++) | ||
| Method Description |
In vivo efficacy of PNU-conjugated ADCs in colorectal CR188 PDX subcutaneous models in NOD/SCID mice. A single dose of 1.0 mg/kg hCD46-19 ADC.
|
||||
| In Vivo Model | Colorectal cancer PDX model (PDX: CR188 PDX) | ||||
| Experiment 4 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) | ≈ 90.48% (Day 30) | Positive CD46 expression (CD46 +++/++) | ||
| Method Description |
In vivo efficacy of PNU-conjugated ADCs in NSCLC LU253 PDX subcutaneous models in NOD/SCID mice. A single dose of 1.0 mg/kg hCD46-19 ADC.
|
||||
| In Vivo Model | Non-small cell lung cancer PDX model (PDX: LU253 PDX) | ||||
Revealed Based on the Cell Line Data
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal Effective Concentration (EC50) | 47.00 pM | Positive CD46 expression (CD46 +++/++) | ||
| Method Description |
Cells were seeded at 5000 per well in a 96-well plate in complete RPMI 1640. Antibody-ZAP complexes (Advanced Targeting Systems; produced according to manufacturer's instructions) or ADCs were added to the cells and plates incubated for 72 hours and 5% carbon dioxide.
|
||||
| In Vitro Model | Normal | HEK293T cells | CVCL_0063 | ||
| Experiment 2 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal Effective Concentration (EC50) | > 3.00 nM | Positive CD46 expression (CD46 +++/++) | ||
| Method Description |
Cells were seeded at 5000 per well in a 96-well plate in complete RPMI 1640. Antibody-ZAP complexes (Advanced Targeting Systems; produced according to manufacturer's instructions) or ADCs were added to the cells and plates incubated for 72 hours and 5% carbon dioxide.
|
||||
| In Vitro Model | Uterine sarcoma | MES-SA cells | CVCL_1404 | ||
References
If you find any error in data or bug in web service, please kindly report it to Dr. Shen et al.